3 hours Vertex Pharmaceuticals (NASDAQ:VRTX) PT Raised to $562.00MarketBeat
UBS Group lifted their price target on shares of Vertex Pharmaceuticals from $477.00 to $562.00 and gave the company a “buy” rating in a research report on Thursday.
Nasdaq 100 · Pharmaceuticals · Science · Vertex (VRTX)
X